← Oncology Approval Tracker

FDA DECISION ·

Epkinly

epcoritamab-bysp · Genmab US

Traditional approvalTraditional conversionFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As a single agent for adults with relapsed or refractory follicular lymphoma after two or more systemic lines.

LAMPGEN ANALYSIS

Why it matters

FDA converted the 2024 accelerated single-agent indication to traditional approval in the same action that added a combination regimen.

What research teams should watch

Document prior systemic lines and ensure the order set uses the monotherapy schedule rather than the distinct combination schedule.

PRIMARY RECORDS

Sources